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An important chapter in the infection–malnutrition story
In this issue of The Lancet Global Health, Jay Berkley 
and colleagues in Kenya present the results of their 
outstanding clinical trial of antibiotic prophylaxis for 
children who recovered from complicated severe acute 
malnutrition (SAM).1 The high rates of mortality and 
nutritional relapse observed among children who 
recover from SAM2,3 have also been seen in children 
recovering from moderate acute malnutrition.4 
These children may require a higher anthropometric 
threshold for recovery,5 which may serve as a marker of 
improved immune status and decreased susceptibility 
to infection.6 
The option tested by Berkley and colleagues is the use 
of prolonged antimicrobial prophylaxis after clinical 
nutritional recovery. The concept of empirical broad-
spectrum antimicrobial therapy in high-risk immuno-
compromised populations is not novel, as there have 
been decades now of demonstrated beneﬁ t of co-
trimoxazole prophylaxis among HIV-infected patients, 
with decreased rates of infection across a range of 
bacterial, fungal, and protozoal pathogens.7,8 More 
recently, two large clinical trials in sub-Saharan Africa 
have demonstrated improvements in rates of nutritional 
recovery9,10 and mortality9 when antibiotics were 
routinely added to nutritional therapy in the acute phase 
of treatment for uncomplicated SAM. Even more broadly, 
antibiotic therapy has been shown in a number of 
randomised trials conducted in low-income and middle-
income settings to improve height and weight gain in 
young children.10 Thus Berkley and colleagues’ results, 
whether positive or negative, add another important 
chapter to the global health community’s collective 
knowledge about the infection–malnutrition link. 
Berkley and colleagues enrolled nearly 1800 HIV-
negative children with complicated SAM and randomised 
them to 6 months of daily co-trimoxazole or placebo 
therapy once they achieved initial inpatient stabilisation. 
Children were followed closely throughout this 6-month 
period and for another 6 months after the intervention 
ended. Follow-up was not only scheduled on a periodic 
basis at the health centres, but also to collect important 
microbiological data. Caretakers were also encouraged 
to bring enrolled children back any time there was an 
acute illness. To improve the completeness of the data 
collected, caretakers were provided with a telephone 
hotline they could contact at any time, as well as ﬁ nancial 
reimbursement for their clinic visits and transportation 
costs.
With regards to the primary outcome of decreasing 
mortality after 12 months, daily co-trimoxazole showed 
no beneﬁ t compared to placebo, with a hazard ratio 
of 0·90 (95% CI 0·71–1·16, p=0·429). Among those 
who survived their initial hospitalisation, a staggering 
8·7% died in the ﬁ rst 6 months of follow-up while 
on co-trimoxazole. Of those who survived those ﬁ rst 
6 months, another 3% perished during the 6 months 
of observation after the study interventions were 
complete. There was a strong trend towards decreased 
mortality in the intervention group during this second 
6-month timespan even though co-trimoxazole 
had been discontinued by that time (hazard ratio 
0·56; 95% CI 0·31–1·02). The total combined rate of 
rehospitalisation or death was 57 per 100 years of 
observation, demonstrating again very clearly how 
vulnerable these children are to continued illness 
despite having achieved nutritional “recovery”. Only 
68% of the subjects were alive and had a mid-upper 
arm circumference above 12·5 cm at the end of the year-
long observation period. Mortality was highest among 
younger children.
The investigators are to be commended for their 
rigorous trial design and thorough implementation. 
When considering the methodological aspects of how 
to conduct an exceptional clinical trial in a resource-
limited setting, future researchers and students should 
look to this study. Among the many strengths of the 
study are its low drop-out rate, a feat likely only achieved 
thanks to the investigators’ heavy investment in the 
human and technological resources to ensure close 
participant tracking. Another powerful feature of the trial 
design was the adaptive sample size based on interim 
blinded independent statistical reviews, allowing the 
investigators to maximise the likelihood that the trial 
would be neither underpowered nor overpowered. 
Berkley and colleagues also did not hesitate to “keep up 
with the times” by updating enrolment criteria for SAM 
in children older than 6 months as the standards of care 
evolved during the course of the study. They also took the 
insightful step of enrolling children as young as 2 months, 
recognising that SAM is a signiﬁ cant problem among 
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children younger than 6 months, that these children have 
extremely high mortality, and that the knowledge base 
on how best to care for these children remains limited.11 
The trial provides a goldmine of information on the 
natural history of post-discharge growth and survival 
for children who recover from SAM—more data than has 
ever previously been collected.
Despite observing a decrease in a number of speciﬁ c 
infections, including skin and soft tissue infections, 
urinary tract infections, and episodes of malaria, 
there was no overall decrease in the frequency of 
outpatient health centre visits or hospital admissions. 
No signiﬁ cant diﬀ erence was observed in the rates 
of bacteraemia between the two groups, and both 
groups demonstrated similarly high rates of co-
trimoxazole-resistant pathogens isolated from blood 
and urine cultures. Despite prior evidence that ponderal 
growth is improved with antibiotics during the initial 
management of uncomplicated SAM,9,10 this was not 
observed during the extended follow-up period of this 
study. The rates of pneumonia were similar between 
the two groups and the co-trimoxazole group had 
signiﬁ cantly more diarrhoea overall and a trend towards 
more severe diarrhoea—ﬁ ndings that may explain why 
no survival or growth beneﬁ t from co-trimoxazole was 
identiﬁ ed. In addition to the higher rate of diarrhoea, 
the co-trimoxazole group did have lower neutrophil 
counts.
Since this study did not demonstrate any survival 
or hospitalisation beneﬁ t from co-trimoxazole for 
children who have recovered from SAM, such empirical 
antibiotic therapy cannot be recommended. In fact, it 
should be explicitly rejected, especially considering the 
potential collateral damage to the individual (potential 
myelo suppression and increased diarrhoea) and to the 
community (increased antimicrobial resistance) from 
such widespread usage. Co-trimoxazole remains under 
investigation as part of a bundle of interventions for 
children discharged from hospital with severe malaria 
in Uganda and Malawi12 and thus there remains the 
possibility that this recommendation might need 
reﬁ nement when those results become available.
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